Meningococcal Vaccine Market, By Type (Bivalent, Quadrivalent and Others), By Brand (Menactra, Menveo, Nimenrix, Trumenba, Bexsero and Others) By Age group ( Infants (0 to 2 year), Children & Adult( 2 or Above), By Distribution (Government and Private), By Vaccine( Polysaccharides, Conjugate, Protein based vaccines), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Meningococcal meningitis (also known as bacterial meningococcal meningitis and epidemic cerebrospinal meningitis) is a form of meningitis caused by a specific bacterium known as Neisseria meningitidis. The bacterium is spread by droplets in the air or close contact with an infected person. Neisseria meningitidis collects in the nasopharynx, or post-nasal space, that connects the nasal cavities with the throat and then this bacterium is transported to the membranes (meninges) around the brain or spinal cord by the blood. It usually spreads from nearby infected areas such as the nasal sinuses or from the cerebrospinal fluid. Meningitis is characterized by inflammation of the membranes (meninges) around the brain or spinal cord. This inflammation can begin suddenly (acute) or develop gradually (sub-acute). Symptoms may include fever, headache, and a stiff neck, sometimes with aching muscles. Nausea, vomiting and other symptoms may also occur. Skin rashes occur in half of all individuals with meningococcal meningitis. Meningococcal meningitis is also associated with a high mortality rate and persistent neurological defects, particularly among infants and young children. Meningococcal meningitis without antibiotic therapy is uniformly fatal. Meningococcal Vaccine Market accounted for US$ 3.0 Billion in 2020 and is estimated to be US$ 7.4 Billion by 2030 and is anticipated to register a CAGR of 9.5%

Rising inclusions in National Immunization Program (NIPs) by governments

Increasing immunization initiatives by government and regulatory authorities to combat the rising prevalence of meningitis is expected to boost the Global Meningococcal Vaccine Market. For instance, the Ministry of health, Government of Australia upgraded NIPs by including Nimenrix-quadrivalent ACWY vaccines to the national immunization program in Australia, thus pushing the sale of vaccines in February 2018.

Greater awareness results in higher demands

Surging healthcare awareness among children, teen and adolescent from getting infected by meningococcal disease points to an influx of opportunities for key players. Increasing number of individual becoming aware regarding this disease triggers the global market, especially worst-hit region.

The Global Meningococcal Vaccine Market is segmented based on type, brand, age-group, distribution and region. On the basis of type, the Global Meningococcal Vaccine Market is segmented into Bivalent, Quadrivalent and Others. Based on brands, the target market is segmented into Menactra, Trumenba, Menveo, Bexsero, Nimenrix and others. On the basis of age-group, the target market is segmented into Infants (0-2 years) and Children & Adult (2 years or above). On the basis of distribution, the market is segmented in Private and Government. On the basis of vaccines, market is segmented in polysaccharides, conjugate, protein based vaccines.

Regional Insights:

Based on region, the Global Meningococcal Vaccine Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the market and accounted with revenue share of 47.9% in 2019 followed by Europe. High support from government and investment in R&D are the driving factors for North America. Several multivalent, conjugate vaccines by Indian and Chinese manufacturers are in the pipeline and if approved and commercialized in other geographies, could increase global access. With several developing countries, including BRICS (Brazil, Russia, India, China, and South Africa) taking significant steps to initiate the development and production of effective treatments, opportunities for manufacturers in these regions are likely to double in the near future. Partnership between key players and leading companies in BRICS countries are likely to boost the Global Meningococcal Vaccine Market.

In AsiaPacific, the market is expected to grow significantly owing to the increasing pediatric population and increasing initiatives from government for the meningococcal vaccines.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented Global Meningococcal Vaccine Market report based on type, brand, age-group, distribution, vaccine and region.

Global Meningococcal Vaccine Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the Global Meningococcal Vaccine Market include Pfizer Inc., Serum Institute of India ltd., Novartis AG, Sanofi, GlaxoSmithKline plc., Merck & Co., Inc. On 19^th August 2020 GSK announced first participate vaccinated in phase 3 clinical trials of its 5-in-1, meningitis ABCWY vaccine. Serum Institute of India is working on a thermostable Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X) for developing countries. Also, the U.S. Food and Drug Administration (FDA) has agreed to review Sanofi’s meningococcal vaccine candidate, MenQuadfi. Previously, in April 2018, Pfizer’s meningococcal vaccine TRUMENBA received the Breakthrough Therapy designation from U.S. FDA for use in children aged 1 to 9 years.

Pfizer has developed a new molecular entity named PF-06886992 for Serogroups ABCWY Meningococcal Infections which is currently in Phase II clinical trials.

Company Profile:

• Serum Institute of India ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Pfizer Inc.
• Novartis AG
• Sanofi
• GlaxoSmithKline plc.
• Merk & co., Inc.

 “*” marked represents similar segmentation in other categories in the respective section